Bioadaptives (BDPT) Cash from Financing Activities (2013 - 2025)

Bioadaptives has disclosed Cash from Financing Activities across 12 years of filings, most recently posting $255000.0 for Q4 2025.

• Cash from Financing Activities for Q4 2025 came in at $255000.0, up 31.37% year-over-year; the trailing twelve-month figure through Dec 2025 was $549115.0 (up 18.8% YoY), and the FY2025 annual result was $555000.0, up 70.14% from the prior year.
• Cash from Financing Activities came in at $255000.0 for Q4 2025 at Bioadaptives, up from $194115.0 in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $255000.0 in Q4 2025 to a low of $30000.0 in Q3 2021.
• The 5-year median for Cash from Financing Activities is $75000.0 (2021), against an average of $93460.5.
• Across the five-year window, Cash from Financing Activities jumped 496.09% in 2021 and slumped 57.49% in 2022, its largest moves.
• Bioadaptives' Cash from Financing Activities stood at $52000.0 in 2021, then tumbled by 35.81% to $33377.0 in 2022, then soared by 403.64% to $168100.0 in 2023, then advanced by 15.48% to $194115.0 in 2024, then surged by 31.37% to $255000.0 in 2025.
• The last three Cash from Financing Activities figures came in at $255000.0 (Q4 2025), $194115.0 (Q4 2024), and $100000.0 (Q3 2024), per Business Quant data.